Table 3 Correlations between molecular biomarkers and clinical activity, as measured by objective response or clinical benefita
From: Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Objective response | Clinical benefit a | |||||
|---|---|---|---|---|---|---|
Yes | No | p-valueb | Yes | No | p-value b | |
Molecular Subtype | 0.056 | 0.002 | ||||
NSMP without RB1/CCNE1 alterations (n = 16) | 8 (50.0%) | 8 (50.0%) | 14 (87.5%) | 2 (12.5%) | ||
NSMP with RB1/CCNE1 alterations (n = 5) | 0 (0.0%) | 5 (100.0%) | 0 (0.0%) | 5 (100.0%) | ||
TP53 mutated (n = 4) | 0 (0.0%) | 4 (100.0%) | 1 (25.0%) | 3 (75.0%) | ||
CDKN2A mutations | 1 | 1 | ||||
Present (n = 2) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | 1 (50.0%) | ||
Absent (n = 23) | 7 (30.4%) | 16 (69.6%) | 14 (60.9%) | 9 (39.1%) | ||
CTNNB1 mutations | 0.194 | 0.018 | ||||
Present (n = 10) | 5 (50.0%) | 5 (50.0%) | 9 (90.0%) | 1 (10.0%) | ||
Absent (n = 15) | 3 (20.0%) | 12 (80.0%) | 6 (40.0%) | 9 (60.0%) | ||
ESR1 alterations | 1 | 0.125 | ||||
Present (n = 4) | 1 (25.0%) | 3 (75.0%) | 4 (100.0%) | 0 (0.0%) | ||
Absent (n = 21) | 7 (33.3%) | 14 (66.7%) | 11 (52.4%) | 10 (47.6%) | ||
ARID1A alterations | 0.156 | 0.659 | ||||
Present (n = 7) | 4 (57.1%) | 3 (42.9%) | 5 (71.4%) | 2 (28.6%) | ||
Absent (n = 18) | 4 (22.2%) | 14 (77.8%) | 10 (55.6%) | 8 (44.4%) | ||
BCOR alterations | 1 | 0.615 | ||||
Present (n = 5) | 2 (40.0%) | 3 (60.0%) | 4 (80.0%) | 1 (20.0%) | ||
Absent (n = 20) | 6 (30.0%) | 14 (70.0%) | 11 (55.0%) | 9 (45.0%) | ||
KRAS mutations | 1 | 0.615 | ||||
Present (n = 5) | 2 (40.0%) | 3 (60.0%) | 4 (80.0%) | 1 (20.0%) | ||
Absent (n = 20) | 6 (30.0%) | 14 (70.0%) | 11 (55.0%) | 9 (45.0%) | ||
PI3K alterations | 0.527 | 0.543 | ||||
Present (n = 22) | 8 (36.4%) | 14 (63.6%) | 14 (63.6%) | 8 (36.4%) | ||
Absent (n = 3) | 0 (0.0%) | 3 (100.0%) | 1 (33.3%) | 2 (66.7%) | ||
